营心宁胶囊联合辛伐他汀治疗高龄男性ASCVD的疗效及对TGF-β1-Smad2/3通路的影响

Therapeutic effect of Yingxinning capsule combined with simvastatin on ASCVD in elderly men and its effect on TGF-β1-Smad2/3 pathway

目的 研究营心宁胶囊治疗高龄男性动脉粥样硬化性心血管疾病(ASCVD)的疗效及对转化生长因子(TGF-β1)-Smad2/3通路的影响。方法 选择高龄男性ASCVD患者,随机分为对照组(辛伐他汀治疗)和联合组(营心宁胶囊联合辛伐他汀治疗)。治疗前及治疗3个月后,分别检测血清总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDLC)、高密度脂蛋白胆固醇(HDLC)、非HDLC、TGF-β1、Smad2、Smad3的水平,比较两组全因死亡及主要不良心血管事件(MACE)的情况。结果 治疗3个月后,两组TC、LDLC、非HDLC、TGF-β1、Smad2、Smad3均较治疗前降低,且联合组LDLC、非HDLC、TGF-β1、Smad2、Smad3低于对照组(P<0.05)。联合组全因死亡及MACE发生率低于对照组(P<0.05)。结论 辛伐他汀联合营心宁胶囊治疗高龄男性ASCVD,可显著降低LDLC并抑制其TGF-β1-Smad2/3通路,显著降低全因死亡及MACE发生率。

Aim To investigate the therapeutic effect of Yingxinning capsule on atherosclerotic cardiovascular disease(ASCVD)and its effect on transforming growth factor(TGF-β1)-Smad2/3 pathway in elderly men.Methods Elderly male patients with ASCVD were selected and randomly divided into control group(simvastatin)and combination group(Yingxinning capsule combined with simvastatin).Serum total cholesterol(TC),triglyceride(TG),low density lipoprotein cholesterol(LDLC),high density lipoprotein cholesterol(HDLC),non-HDLC,TGF-β1,Smad2,Smad3 levels were detected before treatment and 3 months after treatment.All-cause death and major adverse cardiovascular events(MACE)were compared between the two groups.Results At 3 months after treatment,TC,LDLC,non-HDLC,TGF-β1,Smad2,Smad3 in both groups were lower than before treatment,and LDLC,non-HDLC,TGF-β1,Smad2,Smad3 in the combined group were lower than those in the control group(P<0.05).In the combined group,the incidence of all-cause death and MACE was lower than that in the control group(P<0.05).Conclusion Simvastatin combined with Yingxinning capsule in the treatment of ASCVD in elderly men reduced LDLC significantly,inhibited TGF-β1-Smad2/3 pathway significantly,reduced the incidence of all-cause death and MACE.